Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
OKUR Stock Chart & Stats
$2.94
-$0.05(-0.63%)
At close: 4:00 PM EST
$2.94
-$0.05(-0.63%)
Day’s Range― - ―
52-Week Range$1.70 - $17.74
Previous CloseN/A
Volume8.61K
Average Volume (3M)86.56K
Market Cap
$41.94M
Enterprise Value-$50.26M
Total Cash (Recent Filing)$70.33M
Total Debt (Recent Filing)$687.00K
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding12,843,434
10 Day Avg. Volume131,167
30 Day Avg. Volume86,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.10
Price to Sales (P/S)0.00
P/FCF Ratio-2.24
Enterprise Value/Market Cap-1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit79.66
Enterprise Value/Ebitda0.64
Forecast
1Y Price Target
$27.00Price Target Upside818.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's cash position is approximately $83.4 million, which is expected to provide a cash runway into the fourth quarter of 2026.
Market ExpansionOnKure expressed growing interest in expanding to vascular malformations, where there remains an unmet need for highly selective, safe, and effective oral therapies.
Strategic PositioningThe company's expansion into PI3KCA-driven vascular malformations aligns with strategies used by other major players, potentially enhancing its market position.
Bears Say
Competitor PressureCompetitor data from Eli Lilly and Celcuity presented at ESMO 2025 add further pressure to OnKure's upcoming update.
Financial ConcernsOnKure ended Q3 2025 with $70.3M in cash and cash equivalents, which is expected to fund activities into ~1.3 years.
Treatment LimitationsA key disadvantage for OnKure is the IV QW dosing of its treatment compared to competitors' more patient-friendly oral options.
OnKure Therapeutics News
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $1.70 and its highest was $17.74 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $41.94M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Aug 06, 2025 which is 95 days ago.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on May 06, 2025. The company reported -$1.19 earnings per share for the quarter, beating the consensus estimate of -$1.38 by $0.19.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 12,843,434 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$1.19 in its last earnings report, beating expectations of -$1.38. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
OnKure Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (818.37% Upside)
$27.00 (818.37% Upside)
Hedge Fund Trend
Decreased
By 779.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.3%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.51%
12-Months-Change
Fundamentals
Return on Equity
-90.56%
Trailing 12-Months
Asset Growth
9.34%
Trailing 12-Months
Company Description
OnKure Therapeutics
OnKure Therapeutics (OKUR) is a clinical-stage biopharmaceutical company specializing in the discovery and development of targeted oncology therapies. The company focuses on creating innovative small molecule inhibitors that modulate key oncogenic pathways, aiming to provide effective treatments for cancer patients. OnKure's core products are primarily centered around its proprietary drug candidates designed to address unmet medical needs in oncology.
OKUR Stock 12 Month Forecast
Average Price Target
$27.00
▲(818.37% Upside)
Technical Analysis
IGC Pharma
―
Sonnet BioTherapeutics Holdings
―
Aziyo Biologics
―
Rani Therapeutics Holdings
―
Klotho Neurosciences
―
Ownership Overview
27.38% Insiders
6.41% Mutual Funds
<0.01% Other Institutional Investors
60.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---